Survodutide (glucagon/GLP-1 dual agonist) delivers 16.6% weight loss in Phase 3 SYNCHRONIZE-1 (ADA 2026; NEJM + Nature Medicine)

Survodutide Phase 3 SYNCHRONIZE-1: 16.6% weight loss, fat-driven (ADA 2026)

Provenance: Phase 3 RCT — presented at a recognised conference AND peer-reviewed

SYNCHRONIZE-1 results presented at the ADA 2026 Scientific Sessions (June 2026) and simultaneously published in The New England Journal of Medicine and Nature Medicine. Survodutide (BI 456906) is a glucagon/GLP-1 receptor dual agonist (Boehringer Ingelheim, partnered with Zealand Pharma). Higher confidence than topline-only because it is peer-reviewed.

Key findings

• SYNCHRONIZE-1 — 76-week, double-blind, placebo-controlled; 725 adults with obesity/overweight without type 2 diabetes. Mean weight loss up to 16.6% (≈17.8 kg / 39.2 lb) vs 3.2% placebo (statistically significant).
• MRI substudy: weight reduction was predominantly fat — lean mass ≤ 10.8% of total tissue change; visceral fat ↓ up to 34%; liver fat ↓ up to 63.1%.
• Companion trial SYNCHRONIZE-MASLD supported survodutide for liver-fat and body-weight reduction (metabolic dysfunction-associated steatotic liver disease).
• Tolerability: dose-dependent GI adverse events (class-consistent per the sponsor; some analysts flagged tolerability/titration questions at ADA).

Why it matters for this base

• Survodutide is a catalog peptide with previously thin, mostly Phase 2 KB evidence. This is its first Phase 3 obesity readout, peer-reviewed in NEJM + Nature Medicine — real evidence for the glucagon/GLP-1 dual-agonist tier of the Fat Loss / Metabolic cluster.
• Positions survodutide below the triple agonist Retatrutide (~28% in TRIUMPH-1) and dual GIP/GLP-1 Tirzepatide (~22.5%), but its glucagon arm (Glucagon Agonism → hepatic fat / energy expenditure) drives the standout liver-fat (63%) and visceral-fat signals — a MASLD/visceral-fat differentiator worth a comparison angle. Candidate row for the best-glp-1-for-weight-loss-2026-ranked hub.

Caveats

• Sponsor-run; not FDA-approved (investigational). 16.6% is the up-to mean; estimand/dose details in the primary papers. GI tolerability is dose-dependent. Research/educational use only.

Corroborating sources

• Boehringer Ingelheim US newsroom (SYNCHRONIZE-1 + two-trial release); Zealand Pharma / BioSpace press release; primary papers in NEJM and Nature Medicine (ADA 2026); AJMC (Lee Kaplan interview); Managed Healthcare Executive (ADA 2026 — visceral −34%, liver −63%); Fierce Biotech (ADA tolerability coverage); Springer Medicine (SYNCHRONIZE-MASLD).